- Home
- GROV vs MAIA Comparison
GROV vs MAIA Comparison
Compare GROV & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GROV
- MAIA
- Stock Information
- Founded
- GROV 2016
- MAIA 2018
- Country
- GROV United States
- MAIA United States
- Employees
- GROV N/A
- MAIA N/A
- Industry
- GROV Package Goods/Cosmetics
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- GROV Consumer Discretionary
- MAIA Health Care
- Exchange
- GROV Nasdaq
- MAIA Nasdaq
- Market Cap
- GROV 42.2M
- MAIA 46.7M
- IPO Year
- GROV N/A
- MAIA 2022
- Fundamental
- Price
- GROV $1.18
- MAIA $2.01
- Analyst Decision
- GROV Buy
- MAIA
- Analyst Count
- GROV 1
- MAIA 0
- Target Price
- GROV $2.00
- MAIA N/A
- AVG Volume (30 Days)
- GROV 48.4K
- MAIA 320.9K
- Earning Date
- GROV 05-14-2025
- MAIA 05-20-2025
- Dividend Yield
- GROV N/A
- MAIA N/A
- EPS Growth
- GROV N/A
- MAIA N/A
- EPS
- GROV N/A
- MAIA N/A
- Revenue
- GROV $203,425,000.00
- MAIA N/A
- Revenue This Year
- GROV N/A
- MAIA N/A
- Revenue Next Year
- GROV $6.19
- MAIA N/A
- P/E Ratio
- GROV N/A
- MAIA N/A
- Revenue Growth
- GROV N/A
- MAIA N/A
- 52 Week Low
- GROV $1.02
- MAIA $1.40
- 52 Week High
- GROV $1.95
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- GROV 49.41
- MAIA 53.77
- Support Level
- GROV $1.08
- MAIA $1.80
- Resistance Level
- GROV $1.19
- MAIA $2.18
- Average True Range (ATR)
- GROV 0.05
- MAIA 0.30
- MACD
- GROV 0.03
- MAIA -0.01
- Stochastic Oscillator
- GROV 92.86
- MAIA 29.82
About GROV Grove Collaborative Holdings Inc.
Grove Collaborative Holdings Inc is engaged in providing consumer products. It offers Cleaning accessories, Home and Pantry, Personal care products, Pets supplements and Other products. It is a sustainability oriented consumer products generator. It use connection with consumers to create and curate authentic, disruptive brands and products. Company builds natural products that perform as well as, many consumer packaged goods (CPG) brands (both conventional and natural), while being healthier for consumers and the planet.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.